The administration of chemotherapy at reduced doses given at regular, frequent time
intervals, termed 'metronomic'chemotherapy, presents an alternative to standard maximal …

Cimetidine, the first H 2 receptor antagonist in widespread clinical use, has anti-cancer
properties that have been elucidated in a broad range of pre-clinical and clinical studies for …

Neuroblastoma is the most common extra-cranial solid tumor in children. It is a
heterogeneous disease, consisting of neural crest-derived tumors with remarkably different …

Background: The outcome of children with refractory/relapsed malignancies remains poor
and novel therapies are urgently required. One of the promising approaches is metronomic …

Background: Relapses in pediatric high-risk brain tumors remain unmet medical needs.
Over the last 15 years, metronomic chemotherapy has gradually emerged as an alternative …

Mutations of oncogenes and tumor suppressor genes which activate mTOR through several
downstream signaling pathways are common to cancer. Activation of mTOR when combined …

Hepatocellular carcinoma (HCC) is a hypervascular highly angiogenic tumor usually
associated with liver cirrhosis. Vascular endothelial growth factor plays a critical role in …

Background/purpose To determine the maximum tolerated dose, toxicities, and response of
sirolimus combined with oral metronomic therapy in pediatric patients with recurrent and …

In conventional chemotherapy, maximum tolerated dose approach is considered as a first-
line medication for cancer treatment in clinics. In contrast to the conventional chemotherapy …

Metronomic chemotherapy transitioned from the bench to bedside in the early 2000s and
since then has carved a niche for itself in pediatric oncology. It has been used solely or in …